AXS-05 Treatment of Alzheimer's Disease-Related Intensive Phase II/III Trial Accelerated!
-
Last Update: 2020-05-31
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease that initially manifests itself as forgetfulness and then develops into severe cognitive impairment and memory lossIt is estimated that about 5 million people in the United States are affected by AD, and that number is expected to rise to about 14 million by 2050In addition to cognitive decline, patients diagnosed with AD often experience dissofaring behavioral and psychological symptoms, and about 45 percent of patients report aggressive symptomsAggressiveness is characterized by low mood, aggressive behaviour, destructive irritability, and de-suppression (disinhibition)Anxiety in AD patients is associated with increased caregiver burden, reduced function, early placement in nursing homes and increased mortalityThere is currently no FDA-approved treatment for AD patientsoriginal origin: Axsome Therapeutics Causes of THE ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer's Disease Sionooriginal title: Ensuring Patient Safety and Data Integrity! Axsome accelerates completion of AXS-05 treatment of Alzheimer's-related radicals II/III trial!
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.